<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Angiotensin II receptor antagonist,Angiotensin II receptor antagonists,Angiotensin II receptor antagonists,ACE inhibitor,ATC code C09,Adverse drug reaction,Aldosterone,Angioedema,Angiotensin receptor,Australian Medicines Handbook,Bradykinin" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Angiotensin II receptor antagonist - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Angiotensin II receptor antagonist</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <div class="thumb tright">
<div class="thumbinner" style="width:202px;"><a href="../../../l/o/s/Image%7ELosartan_structure.png_1dcf.html" class="internal" title="Losartan, the first ARB"><img src="../../../upload/thumb/4/4a/Losartan_structure.png/200px-Losartan_structure.png" alt="Losartan, the first ARB" width="200" height="228" longdesc="../../../l/o/s/Image%7ELosartan_structure.png_1dcf.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../l/o/s/Image%7ELosartan_structure.png_1dcf.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Losartan, the first ARB</div>
</div>
</div>
<p><b>Angiotensin II receptor antagonists</b>, also known as <b>angiotensin receptor blockers</b> (ARBs), <b>AT<sub>1</sub>-receptor antagonists</b> or <b>sartans</b>, are a group of pharmaceuticals which modulate the <a href="../../../r/e/n/Renin-angiotensin-aldosterone_system.html" title="Renin-angiotensin-aldosterone system">renin-angiotensin-aldosterone system</a>. Their main use is in <a href="../../../h/y/p/Hypertension.html" title="Hypertension">hypertension</a> (high blood pressure), <a href="../../../d/i/a/Diabetic_nephropathy.html" title="Diabetic nephropathy">diabetic nephropathy</a> (kidney damage due to <a href="../../../d/i/a/Diabetes_mellitus.html" title="Diabetes mellitus">diabetes</a>) and <a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">congestive heart failure</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Mode_of_action"><span class="tocnumber">1</span> <span class="toctext">Mode of action</span></a></li>
<li class="toclevel-1"><a href="#Uses"><span class="tocnumber">2</span> <span class="toctext">Uses</span></a></li>
<li class="toclevel-1"><a href="#Adverse_effects"><span class="tocnumber">3</span> <span class="toctext">Adverse effects</span></a></li>
<li class="toclevel-1"><a href="#Members"><span class="tocnumber">4</span> <span class="toctext">Members</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Mode_of_action" id="Mode_of_action"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Edit section: Mode of action">edit</a>]</span> <span class="mw-headline">Mode of action</span></h2>
<p>These substances are AT<sub>1</sub>-receptor antagonists – that is, they block the activation of <a href="../../../a/n/g/Angiotensin_receptor.html" title="Angiotensin receptor">angiotensin II AT<sub>1</sub> receptors</a>. Blockade of AT<sub>1</sub> receptors directly causes <a href="../../../v/a/s/Vasodilation.html" title="Vasodilation">vasodilation</a>, reduces secretion of <a href="../../../v/a/s/Vasopressin.html" title="Vasopressin">vasopressin</a>, reduces production and secretion of <a href="../../../a/l/d/Aldosterone.html" title="Aldosterone">aldosterone</a>, amongst other actions – the combined effect of which is reduction of blood pressure.</p>
<p>The specific efficacy of each ARB within this class is made up of a combination of three pharmacodynamic and pharmacokinetic parameters. These areas are: 1) Pressor inhibition (at trough or the 24th hour) this clinically important measurement relates to the amount of blockade or inhibition of the BP raising effect of angiotension II. The rates as listed in the US FDA Package Inserts for inhibition of this effect at the 24th hour for the ARBs are as follows:(all doses listed in PI are included)</p>
<ul>
<li>Valsartan 80mg 30%</li>
<li>Telmisartan 80mg 40%</li>
<li>Losartan 100mg 25- 40%</li>
<li>Irbesartan 150mg 40%</li>
<li>Irbesartan 300mg 60%</li>
<li>Olmesartan 20mg 61%</li>
<li>Olmesartan 40mg 74%</li>
</ul>
<p>2) AT1 affinity, AT1 affinity vs AT2 is the second meaningful area out of three that make up the efficacy of an individual ARB. The specific AT1 affinity relates to how specificially attracted the medicine is for the correct receptor, the US FDA Package Insert rates for AT1 affinity are as follows:</p>
<ul>
<li>Losartan 1000 fold</li>
<li>Telmisartan 3000 fold</li>
<li>Irbesartan 8500 fold</li>
<li>Olmesartan 12500 fold</li>
<li>Valsartan 20000 fold</li>
</ul>
<p>3) The third area that completes the overall efficacy picture of an ARB is half life. Half life is an indicator of how many hours it takes for half the medicine to still be effective. The rates from the US FDA Package Inserts are as follows:</p>
<ul>
<li>Valsartan 6</li>
<li>Losartan 6- 9</li>
<li>Irbesartan 11- 15</li>
<li>Olmesartan 13</li>
<li>Telmisartan 24</li>
</ul>
<p>Based on the above data for the three key PD/ PK areas that indicate efficacy it is important to see that you need a combination of all three at a effective level.</p>
<p><a name="Uses" id="Uses"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Edit section: Uses">edit</a>]</span> <span class="mw-headline">Uses</span></h2>
<p>Angiotensin II receptor antagonists are primarily used for the treatment of <a href="../../../h/y/p/Hypertension.html" title="Hypertension">hypertension</a> where the patient is intolerant of <a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="ACE inhibitor">ACE inhibitor</a> therapy. They do not inhibit the breakdown of <a href="../../../b/r/a/Bradykinin.html" title="Bradykinin">bradykinin</a> or other <a href="../../../k/i/n/Kinin.html" title="Kinin">kinins</a>, and are thus only rarely associated with the persistent dry cough and/or <a href="../../../a/n/g/Angioedema.html" title="Angioedema">angioedema</a> that limit ACE inhibitor therapy. More recently, they have been used for the treatment of <a href="../../../h/e/a/Heart_failure.html" title="Heart failure">heart failure</a> in patients intolerant of ACE inhibitor therapy, particularly <a href="../../../c/a/n/Candesartan.html" title="Candesartan">candesartan</a>. Irbesartan and losartan have trial data showing benefit in hypertensive patients with type II diabetes, and may delay the progression of <a href="../../../d/i/a/Diabetic_nephropathy.html" title="Diabetic nephropathy">diabetic nephropathy</a>.</p>
<p>The angiotensin II receptor blockers have differing potencies in relation to blood pressure control, with statistically differing blood pressure effects at the maximal doses.<sup id="_ref-Kassler-Taub-1998_0" class="reference"><a href="#_note-Kassler-Taub-1998" title="">[1]</a></sup> When used in clinical practice, the particular agent used may vary based on the degree of blood pressure response required.</p>
<p><a name="Adverse_effects" id="Adverse_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Edit section: Adverse effects">edit</a>]</span> <span class="mw-headline">Adverse effects</span></h2>
<p>This class of drugs is usually well-tolerated, with common <a href="../../../a/d/v/Adverse_drug_reaction.html" title="Adverse drug reaction">adverse drug reactions</a> (ADRs) including: dizziness, headache, and/or <a href="../../../h/y/p/Hyperkalaemia.html" title="Hyperkalaemia">hyperkalaemia</a>. Infrequent ADRs associated with therapy include: first dose <a href="../../../o/r/t/Orthostatic_hypotension.html" title="Orthostatic hypotension">orthostatic hypotension</a>, rash, diarrhoea, <a href="../../../d/y/s/Dyspepsia.html" title="Dyspepsia">dyspepsia</a>, abnormal liver function, muscle cramp, <a href="../../../m/y/a/Myalgia.html" title="Myalgia">myalgia</a>, back pain, <a href="../../../i/n/s/Insomnia.html" title="Insomnia">insomnia</a>, decreased <a href="../../../h/a/e/Haemoglobin.html" title="Haemoglobin">haemoglobin</a> levels, <a href="../../../r/e/n/Renal_impairment.html" title="Renal impairment">renal impairment</a>, <a href="../../../p/h/a/Pharyngitis.html" title="Pharyngitis">pharyngitis</a>, and/or nasal congestion. (Rossi, 2006)</p>
<p>While one of the main rationales for the use of this class is the avoidance of dry cough and/or angioedema associated with ACE inhibitor therapy, they may still rarely occur. Additionally, there is also a small risk of cross-reactivity in patients who have experienced <a href="../../../a/n/g/Angioedema.html" title="Angioedema">angioedema</a> with ACE inhibitor therapy. (Rossi, 2006)</p>
<p><a name="Members" id="Members"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Edit section: Members">edit</a>]</span> <span class="mw-headline">Members</span></h2>
<ul>
<li><a href="../../../c/a/n/Candesartan.html" title="Candesartan">Candesartan</a></li>
<li><a href="../../../e/p/r/Eprosartan.html" title="Eprosartan">Eprosartan</a></li>
<li><a href="../../../i/r/b/Irbesartan.html" title="Irbesartan">Irbesartan</a></li>
<li><a href="../../../l/o/s/Losartan.html" title="Losartan">Losartan</a></li>
<li><a href="../../../o/l/m/Olmesartan.html" title="Olmesartan">Olmesartan</a></li>
<li><a href="../../../t/e/l/Telmisartan.html" title="Telmisartan">Telmisartan</a></li>
<li><a href="../../../v/a/l/Valsartan.html" title="Valsartan">Valsartan</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-Kassler-Taub-1998"><b><a href="#_ref-Kassler-Taub-1998_0" title="">^</a></b> <cite style="font-style:normal">Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. (1998). "Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.". <i>Am J Hypertens</i> <b>11</b> (4 Pt 1): 445-53. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9607383" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9607383">PMID 9607383</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Comparative+efficacy+of+two+angiotensin+II+receptor+antagonists%2C+irbesartan+and+losartan+in+mild-to-moderate+hypertension.+Irbesartan%2FLosartan+Study+Investigators.&amp;rft.title=Am+J+Hypertens&amp;rft.jtitle=Am+J+Hypertens&amp;rft.date=1998&amp;rft.volume=11&amp;rft.issue=4+Pt+1&amp;rft.au=Kassler-Taub+K%2C+Littlejohn+T%2C+Elliott+W%2C+Ruddy+T%2C+Adler+E.&amp;rft.pages=445-53">&#160;</span></li>
</ol>
</div>
<ul>
<li>Rossi S, editor. <a href="../../../a/u/s/Australian_Medicines_Handbook_0c4c.html" title="Australian Medicines Handbook">Australian Medicines Handbook</a> 2006. Adelaide: Australian Medicines Handbook; 2006.</li>
<li><a href="http://www.medscape.com/viewarticle/484537_3" class="external text" title="http://www.medscape.com/viewarticle/484537_3" rel="nofollow">Cough and Angioedema From ACE Inhibitors</a></li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#ccccff;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../a/n/g/Template%7EAngiotensin_II_receptor_antagonists_7e4e.html" title="Template:Angiotensin II receptor antagonists"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../a/n/g/Template%7EAngiotensin_II_receptor_antagonists_7e4e.html" class="external text" title="http://en.wikipedia.org../../../a/n/g/Template%7EAngiotensin_II_receptor_antagonists_7e4e.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><strong class="selflink">Angiotensin II receptor antagonists</strong> (</b>AIIRA<b>) (<a href="../../../a/t/c/ATC_code_C09_6c4b.html#C09C_Angiotensin_II_antagonists.2C_plain" title="ATC code C09">C09C</a>)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../c/a/n/Candesartan.html" title="Candesartan">Candesartan</a>, <a href="../../../e/p/r/Eprosartan.html" title="Eprosartan">Eprosartan</a>, <a href="../../../i/r/b/Irbesartan.html" title="Irbesartan">Irbesartan</a>, <a href="../../../l/o/s/Losartan.html" title="Losartan">Losartan</a>, <a href="../../../o/l/m/Olmesartan.html" title="Olmesartan">Olmesartan</a>, Tasosartan, <a href="../../../t/e/l/Telmisartan.html" title="Telmisartan">Telmisartan</a>, <a href="../../../v/a/l/Valsartan.html" title="Valsartan">Valsartan</a></p>
</div>
</div>

<!-- 
Pre-expand include size: 10072 bytes
Post-expand include size: 7629 bytes
Template argument size: 2939 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html">http://en.wikipedia.org../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../a/n/g/Category%7EAngiotensin_II_receptor_antagonists_bc8a.html" title="Category:Angiotensin II receptor antagonists">Angiotensin II receptor antagonists</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/n/g/Talk%7EAngiotensin_II_receptor_antagonist_4f60.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Angiotensin_II_receptor_antagonist">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/a/t/1/AT1-Antagonist_411e.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/a/n/t/Antagoniste_des_r%C3%A9cepteurs_de_l%27angiotensine_II_3fad.html">Français</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/a/n/g/Angiotensine_receptor_blocker.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/s/a/r/Sartany.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/a/n/t/Antagonista_do_receptor_da_angiotensina.html">Português</a>
	      </li>
	      	      <li>
	      <a href="../../../../th/%E0%B9%81/%E0%B8%AD/%E0%B8%87/%E0%B9%81%E0%B8%AD%E0%B8%87%E0%B8%81%E0%B8%B4%E0%B9%82%E0%B8%AD%E0%B9%80%E0%B8%97%E0%B8%99%E0%B8%8B%E0%B8%B4%E0%B8%99%E0%B8%A3%E0%B8%B5%E0%B9%80%E0%B8%8B%E0%B8%9E%E0%B9%80%E0%B8%95%E0%B8%AD%E0%B8%A3%E0%B9%8C%E0%B8%9A%E0%B8%A5%E0%B9%8A%E0%B8%AD%E0%B8%84%E0%B9%80%E0%B8%81%E0%B8%AD%E0%B8%A3%E0%B9%8C.html">ไทย</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 21:03, 22 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../r/a/d/User%7ERadiant%21_e591.html" title="User:Radiant!">Radiant!</a>, <a href="../../../b/o/b/User%7EBobo192_c260.html" title="User:Bobo192">Bobo192</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../b/r/h/User%7EBrholden_e08b.html" title="User:Brholden">Brholden</a>, <a href="../../../t/h/i/User%7EThijs%21bot_bdf4.html" title="User:Thijs!bot">Thijs!bot</a>, <a href="../../../n/o/n/User%7ENongBot_a16b.html" title="User:NongBot">NongBot</a>, <a href="../../../s/t/b/User%7ESTBotD_8c4f.html" title="User:STBotD">STBotD</a>, <a href="../../../j/e/r/User%7EJeroenvrp_e4de.html" title="User:Jeroenvrp">Jeroenvrp</a>, <a href="../../../d/a/v/User%7EDavidruben_76a6.html" title="User:Davidruben">Davidruben</a>, <a href="../../../t/e/c/User%7ETechelf_1565.html" title="User:Techelf">Techelf</a>, Jamiestrachan, <a href="../../../t/a/v/User%7ETavilis_4b00.html" title="User:Tavilis">Tavilis</a>, <a href="../../../y/u/r/User%7EYurikBot_b393.html" title="User:YurikBot">YurikBot</a>, <a href="../../../u/t/h/User%7EUthbrian_6843.html" title="User:Uthbrian">Uthbrian</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../b/r/i/User%7EBrim_2417.html" title="User:Brim">Brim</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../s/a/l/User%7ESalvadorjo_220f.html" title="User:Salvadorjo">Salvadorjo</a>, <a href="../../../f/l/a/User%7EFlaBot_747f.html" title="User:FlaBot">FlaBot</a>, <a href="../../../c/e/y/User%7ECeyockey_fb55.html" title="User:Ceyockey">Ceyockey</a>, <a href="../../../b/l/u/User%7EBluemoose_d309.html" title="User:Bluemoose">Bluemoose</a>, <a href="../../../d/i/b/User%7EDiberri_3d04.html" title="User:Diberri">Diberri</a> and <a href="../../../p/f/h/User%7EPFHLai_0319.html" title="User:PFHLai">PFHLai</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
